Citius Pharma Q3 FY26: LYMPHIR revenue $1.5M, net loss $8.9M, cash $17M

Citius Pharmaceuticals, Inc.

2026-Q3 EPS reported -$1.64 revenue$7,105,197

Q3 FY26 revenue $1.5M from LYMPHIR (vs $0 prior year); nine-month revenue $7.1M.
Net loss $8.9M ($0.34/share) for Q3; $38.3M ($1.64/share) for nine months.
Cash and equivalents $17.0M at June 30, 2026; raised $4.5M offering, $9.7M warrants, $10M loan.
LYMPHIR now at 44 institutions; institutional vial orders up 31%, new institutions up 80%; July orders 383 vials.
G&A includes $19.7M non-recurring contract cancellation charge in March 2026; commercial team expanded to 29.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.